This DVA Stock Forecast article was written by Milana Ledova – Financial Analyst at I Know First.

Highlights

• Consistent Revenue & Earnings Growth: Over the past decade, DaVita has experienced steady revenue and EPS growth driven by increased demand for dialysis services and operational efficiencies.
• Market Leadership in Renal Care: Serving over 210,000 patients across more than 2,800 dialysis centers, DaVita remains one of the largest and most trusted providers in the U.S. and select international markets.
• Shareholder Returns & Operational Efficiency: The company has a solid record of returning cash to shareholders via dividends and share repurchases.

Overview

DaVita Inc. is a leading provider of kidney dialysis services and related care, operating an extensive network of outpatient dialysis centers throughout the United States and internationally. The company’s core business is the provision of life-sustaining dialysis treatments to patients with end‐stage renal disease (ESRD). In addition to its clinical services, DaVita has been expanding its integrated care offerings, including value-added healthcare management programs and technology-driven patient care solutions.

Financial Performance: A Decade of Growth

Over the last ten years, DaVita has delivered solid growth in both top-line revenue and earnings per share (EPS). For example:

• Revenue Growth: DaVita’s revenue has grown by approximately 50% over the past decade, reaching an estimated $12.7 billion in 2024, a 6.34% increase year-over-year.
• EPS Expansion: The EPS has increased from $1.05 per share in 2015 to an average estimated $11.4 per share in 2025.

Diversified Business Model & Service Expansion

DaVita has effectively diversified its business beyond traditional dialysis services. Key initiatives include:

• Integrated Care Services: Expanding into coordinated care management and wellness programs designed to improve patient outcomes and reduce hospitalizations.
• Technological Advancements: Leveraging digital health technologies and data analytics to optimize treatment protocols and enhance patient engagement.
• Operational Efficiency: Continued investments in facility upgrades and streamlined operational processes have boosted both patient care quality and profitability

Overall, the data suggests stable revenue growth and controlled cost increases, but with rising G&A expenses that need monitoring. DaVita must focus on efficiency and payer mix management to sustain margins in a slow-growth dialysis market.

Market Position & Competitive Landscape

DaVita stands as one of the dominant players in the renal care market in the U.S. With over 265,400 patients served and a network of more than 4,114 dialysis centers, in 2024, the company benefits from significant economies of scale and a strong brand reputation among patients and healthcare providers. Its diversified revenue streams and focus on integrated care set it apart from traditional single-service providers.

Profitability

Da Vita’s high Return on Equity (ROE) places it among the top-performing companies in the Healthcare Providers & Services industry and the broader Healthcare sector. This strong performance suggests an efficient use of equity capital, allowing the company to generate superior returns compared to many of its peers.

Key Drivers of DaVita’s ROE:

• Operational Efficiency: DaVita benefits from a well-optimized cost structure and scale advantages in the dialysis market, which contribute to profitability.
• Market Positioning: As a leading provider of kidney care services, DaVita enjoys a stable revenue stream, supported by long-term demand for its treatments.
• Financial Leverage: A high ROE may indicate the strategic use of debt to amplify returns, a common practice in capital-intensive healthcare businesses.

Potential Risks and Considerations:

• Leverage Dependency: If DaVita’s ROE is significantly driven by debt rather than organic profitability, this could introduce financial risk, particularly in a rising interest rate environment.
• Regulatory and Reimbursement Risks: Given its reliance on Medicare and insurance reimbursements, any adverse regulatory changes could pressure margins and future returns.
• Sustainability of Growth: While a high ROE is positive, its long-term sustainability depends on continued operational improvements rather than just financial structuring.

Technological & Service Innovations in Renal Care

DaVita continues to invest in innovative care models and technological improvements that not only enhance patient outcomes but also drive operational efficiencies. Recent initiatives include:

• Digital Health Platforms: Deployment of telemedicine and remote patient monitoring tools that have become critical in today’s healthcare landscape.
• Personalized Care Programs: Implementation of data-driven treatment protocols designed to reduce complications and hospital readmission rates.

DCF Valuation & Target Stock Price

Is DaVita a buy or a sell?

The Discounted Cash Flow (DCF) valuation of DaVita Inc (DVA) is 180,8 USD. With the latest stock price at 147,02 USD, the upside of DaVita Inc based on DCF is 23%. This means that DaVita is a buy according to the DCF valuation model.

Relative Valuation

We compared DVA to its peers in the healthcare services sector (including Hims & Hers Health Inc, Fresenius Medical Care AG, Chemed Corporation, Option Care Health Inc., Guardant Health Inc). Key relative valuation metrics include:

Based on the information above, DVA’s target price is $338.37. Currently, APD stock trades at $147.02 that generates upside of 130%.

Analyst Consensus & Market Sentiment

According to data aggregated from Yahoo Finance and other financial platforms, the majority of analysts rate DVA as a “Hold” with an average price of $163.26

Conclusion

DaVita Inc. is a dominant player in the renal care market with a strong track record of revenue and EPS growth, operational efficiency, and shareholder returns. Our DCF and relative valuation analyses indicate that DVA is currently undervalued, with a 23% upside from current levels. Given its market leadership, ongoing technological innovations, and solid financial performance, we recommend a Buy position on DVA stock.

It is worth paying attention that the stock-picking AI of I Know First has a weak signal on the one-year market trend forecasts. The light red is mildly bearish bullish signal for the one-year forecast.

Past Success with DVA Stock Forecast

I Know First has been bullish on the DVA stock forecast in the past. On March 5^th, 2024 the I Know First algorithm issued a forecast for DVA stock price and recommended DVA as one of the best Warren Buffett Portfolio stocks to buy. The AI-driven DVA stock prediction was successful on a 1-year time horizon, resulting in more than 11.35%.

To subscribe today click here.

Please note-for trading decisions use the most recent forecast.